Dr. Glen Armstrong, Professor of Medical Microbiology, University of Alberta
Dr. Malcolm Rollins, Project Manager in Fermentation, Alberta Research Council
Brian Manning, Account Manager in Technology Commercialization, Alberta Research Counci
AUDIO: Download Audio (mp3 format)
ITEM:1TITLE: Dr. Glen Armstrong, Professor of Medical Microbiology, University of Alberta
SUBJECT: #8 Synsorb and Walkerton
SYNOPSIS: During the Walkerton crisis last spring, an experimental treatment developed by Dr. Glen Armstrong at the University of Alberta was offered on compassionate grounds to victims suffering from e. coli 0157 that tainted their drinking water. 0157 causes bloody diarhea that leads to death. Synsorb, a "sugar coated sand" that soaks up e.coli toxins in the human gut, is just one result of the leading edge research Glen is doing to understand how rogue e.coli and other microorganisms create infection in humans.
ITEM:2TITLE: Dr. Malcolm Rollins, Project Manager in Fermentation, Alberta Research Council
SUBJECT: #8 ARC Research on Vaccinating Cattle for ecoli 0157
SYNOPSIS: The source of e. coli 0157 that is so deadly to humans is cattle. The bacteria has no negative effect on cattle. It can spread to humans through tainted meat or when runoff from manure gets into the water system. A robust organism, e.coli 0157 can then migrate into drinking water or infect vegetable and berry crops when they are sprayed with contaminated irrigation water. Researchers at UBC have discovered a vaccine for cattle which would stop the infection at its source. The next step towards commercialization of the vaccine has been turned over to the Alberta Research Council. Dr. Malcolm Rollins is responsible for the scientific work involved in developing the technology for scaling up production so that millions of doses of the cattle vaccine can be manufactured.
ITEM:3TITLE: Brian Manning, Account Manager in Technology Commercialization, Alberta Research Council
SUBJECT: #8 ARC technology commercialization of e coli vaccine for cattle
SYNOPSIS: The Alberta Research Council is one of a consortium of partners involved in commercializing the cattle vaccine for e. coli 0157. Brian Manning looks after the business end of the technology commercialization process which is a significant investment for the ARC. Overwhelming as it may sound, vaccinating 30 million cattle makes more sense than some of the other options available to prevent e.coli 0157 infection in humans.